ArticleCell communication and signaling : CCS2026
BIRC6 prevents GSDME-mediated pyroptosis and promotes cisplatin resistance via a non-canonical UBC domain-dependent steric hindrance.
Article in Cell communication and signaling : CCS, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
backgroundPyroptosis, particularly gasdermin E (GSDME)-mediated programmed cell death, has emerged as a crucial determinant of chemosensitivity and antitumor immunity. Although baculoviral inhibitor of apoptosis protein (IAP) repeat-containing protein 6 (BIRC6) is a known inhibitor of apoptosis, its potential role in regulating the pyroptotic switch and cisplatin resistance in lung adenocarcinoma (LUAD) remains unclear. Therefore, in this study, we aimed to elucidate the molecular mechanism underlying BIRC6-mediated regulation of pyroptosis and cisplatin resistance in LUAD.
methodsWe integrated bioinformatics analysis, proteomics, and structural modeling with CRISPR-Cas9-mediated mutagenesis to dissect the interplay between BIRC6 and pyroptosis. Subsequently, we functionally validated the interaction between BIRC6 and pyroptosis using cisplatin-resistant LUAD cell lines and xenograft models.
resultsWe observed that BIRC6 was aberrantly upregulated in cisplatin-resistant LUAD tissues and correlated with poor clinical prognosis. Functionally, while BIRC6 knockdown resensitized resistant LUAD cells to cisplatin by restoring GSDME-dependent pyroptosis, its overexpression in sensitive cells stifled this pathway to confer resistance. Mechanistically, rather than promoting ubiquitin-proteasomal degradation, BIRC6 physically interacted with the N-terminal pore-forming domain of GSDME via its ubiquitin-conjugating domain. Structural analysis revealed that this interaction created steric hindrance that masked the specific caspase-3 cleavage site on GSDME, thereby preventing the occurrence of pyroptosis. Disruption of the BIRC6-GSDME interface effectively restored pyroptosis and triggered robust inflammatory cell death, which subsequently enhanced cisplatin efficacy in vivo.
conclusionOur findings uncovered a non-canonical mechanism wherein BIRC6 structurally locks GSDME in an inactive state to confer cisplatin resistance. Consequently, targeting the BIRC6-GSDME interface offers a novel therapeutic strategy to trigger pyroptosis and overcome chemotherapy resistance in LUAD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.